Mahzi Therapeutics Challenges Biotech Norms by Letting Rare Disease Families Invest in Gene Therapy

Mahzi Therapeutics, a clinical-stage biotech developing gene therapies for rare neurodevelopmental disorders, is pioneering a model that allows affected families to become shareholders through Regulation Crowdfunding. Led by Yael Weiss, the company is currently dosing patients in the first-ever gene therapy trial for Pitt Hopkins syndrome. Half of the early reservations in its $10 million bridge round came from parents, highlighting the shift from passive recipients to active financial stakeholders. The firm has raised $60 million from investors including Venrock, HealthCap, and HBM Partners, alongside $8 million in non-dilutive grants. Mahzi’s approach, which integrates patient input into trial design and leverages community funding, targets over 800 rare neurogenetic disorders in a $16 billion-plus market. By rejecting traditional venture capital reliance, the model seeks to commercialize therapies that large pharma deems economically unviable. Weiss emphasizes that success lies not only in treating patients but in forming partnerships with advocacy groups to advance their science. This experiment tests whether patients can hold value, not just receive it.